Omalizumab prevents anaphylactoid reactions to mRNA COVID-19 vaccine.

Smola, A; Samadzadeh, S; Müller, L; Adams, O; Homey, B; Albrecht, P; Meller, S

Smola, A; Samadzadeh, S; Müller, L; Adams, O; Homey, B; Albrecht, P; Meller, S.

Afiliación

Smola A; Department of Dermatology, Medical Faculty, Heinrich-Heine-University, Duesseldorf, Germany.
Samadzadeh S; Department of Neurology, Medical Faculty, Heinrich-Heine-University, Duesseldorf, Germany.
Müller L; Institute of Virology, Medical Faculty, Heinrich-Heine-University, Duesseldorf, Germany.
Adams O; Institute of Virology, Medical Faculty, Heinrich-Heine-University, Duesseldorf, Germany.
Homey B; Department of Dermatology, Medical Faculty, Heinrich-Heine-University, Duesseldorf, Germany.
Albrecht P; Department of Neurology, Medical Faculty, Heinrich-Heine-University, Duesseldorf, Germany.
Meller S; Department of Dermatology, Medical Faculty, Heinrich-Heine-University, Duesseldorf, Germany.

J Eur Acad Dermatol Venereol ; 35(11): e743-e745, 2021 Nov.

Article en En | MEDLINE | ID: mdl-34310766

Asunto(s)

Anafilaxia; COVID-19; Anafilaxia/inducido químicamente; Anafilaxia/prevención & control; Vacunas contra la COVID-19; Humanos; Omalizumab/efectos adversos; ARN Mensajero; SARS-CoV-2

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: COVID-19 / Anafilaxia Límite: Humans Idioma: En Revista: J Eur Acad Dermatol Venereol Asunto de la revista: DERMATOLOGIA / DOENCAS SEXUALMENTE TRANSMISSIVEIS Año: 2021 Tipo del documento: Article País de afiliación: Alemania Pais de publicación: Reino Unido

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google